Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2757 - Severe Oral Mucositis (SOM) Mitigation by Genetically Modified Lactococcus Lactis Bacteria (LLB) Producing Human Trefoil Factor 1 (hTFF1; AG013) in Patients Being Treated With Concomitant Chemoradiation (CRT) for Oral and Oropharyngeal Cancers (OCOPC)

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Tumour Site

Head and Neck Cancers

Presenters

Suraj Singh

Citation

Annals of Oncology (2019) 30 (suppl_5): v449-v474. 10.1093/annonc/mdz252

Authors

S. Singh1, S. Nuyts2, R. Doline3, S. Satti4, M. Schwartz5, S. Thatcher6, Y. Chen7, S. Katz8, M. Garg9, J. Wagemans10, P. Specenier11, C. Wittekindt12, L. Lee13, J. Reifler14, S. Sonis15, M. Emanuel16, F. Cilli16, A. Joslyn17, J. Wade18

Author affiliations

  • 1 Radiation Oncology, Multicare Regional Cancer Center, 98405 - Tacoma/US
  • 2 Radiation Oncology, University Hospital Leuven, 3000 - Leuven/BE
  • 3 Radiation Oncology, CaroMont Health System, 28054 - Gastonia/US
  • 4 Medical Oncology, Ochsner Medical Center, 70121 - New Orleans/US
  • 5 Radiation Oncology, Comprehensive Cancer Centers of Nevada-Henderson, 89052 - Henderson/US
  • 6 Radiation Oncology, Cancer Care Northwest, 99216 - Spokane Valley/US
  • 7 Radiation Oncology, University of Rochester Medical Center, 14642 - Rochester/US
  • 8 Radiation Oncology, Willis-Knighton Cancer Center, 71103 - Shreveport/US
  • 9 Radiation Oncology, Montifiore Medical Center, 10467 - Bronx/US
  • 10 Medical Oncology, St. Maarten General Hospital, 2570 - Mechelen/BE
  • 11 Medical Oncology, University Hospital Antwerp, B-2650 - Edegem/BE
  • 12 Otorhinolaryngology, University Hospital Giessen, 35390 - Giessen/DE
  • 13 Clinical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 14 Consulting Chief Medical Officer, PSI, Inc., 19406 - King of Prussia/US
  • 15 Dentistry Consultant, Primary Endpoint Solutions, 02471 - Watertown/US
  • 16 Clinical Operations, Oragenics, 33634 - Tampa/US
  • 17 Oragenics, Inc., Oragenics, Inc., 33634 - Tampa/US
  • 18 Radiation Oncology, Decatur Memorial Hospital, 62526 - Decatur/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2757

Background

SOM is a devasting consequence of CRT. hTFF1 is a naturally occurring protein that can protect the mucosa. LLB were genetically modified (GM) to produce hTFF1, formulated as an oral rinse and attenuated SOM in patients receiving chemotherapy. The GM LLB lack all necessary components for survival and multiplication. The objective of this ongoing Phase 2 trial is to assess the safety and efficacy of AG013 as a SOM intervention.

Methods

This is a double-blind, randomized, placebo-controlled trial recruiting ∼200 patients with OCOPC at 48 sites (US and Europe). Patients (PTS) receive cumulative RT (cumRT) between 50 Gy – 72 Gy, 2.0-2.2 Gy QD + QW/Q3W cisplatin. At least two mucosal sites at risk of SOM receive minimal cumRT of 50 Gy. PTS are randomized 1:1 to receive placebo or AG013 [LLB strain sAGX0085 engineered to secrete hTFF1 (2x1011 CFU/15 mL tid)] starting on CRT day 1 and continuing 2 weeks post-CRT. Beginning on CRT day 1 and continuing Q2W until resolution, OM is assessed by trained assessors and scores assigned centrally. The primary and secondary efficacy endpoints are SOM duration and incidence (WHO criteria). AEs are described by NCI-CTCv4. A DSMB performed a safety analysis following accrual of the first 24 PTS. Tumor response to CRT is evaluated for 1-year post CRT.

Results

71 PTS have been randomized across 48 study sites. Complete OM data are available for 42 PTS for whom blinded evaluation (active and placebo) demonstrated an overall SOM incidence of 52%. SOM was noted at 81 of 547 visits (14.8%). 25 PTS have stopped active treatment; 2 for non-compliance, 5 for AEs, and 18 lost to follow-up or unwilling or unable to conform to the protocol. Unexpected SAEs were noted in 9 PTS. No study drug-associated cases of bacteremia or sepsis were seen. DSMB review after the first 24 PTS concluded that there were no contraindications to study continuance.

Conclusions

Observations based on blinded data suggest that AG013 offers a safe, well-tolerated, and potentially efficacious platform to deliver an effective protein intervention for SOM mitigation.

Clinical trial identification

AG013-ODOM-201.

Editorial acknowledgement

Legal entity responsible for the study

Oragenics, Inc.

Funding

Oragenics, Inc.

Disclosure

S. Sonis: Advisory / Consultancy, consultant: Oragenics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.